Exserohilum species are soilborne fungi that have been uncommon causes of human disease. The ongoing outbreak in the United States warrants improved understanding of this pathogen. We systematically reviewed all cases of Exserohilum spp. infections published before the outbreak in 2012 in order to provide a better understanding of the organism and its wider spectrum of human disease. Cases of Exserohilum infections were retrieved by searching PubMed. Demographic data, underlying conditions, microbiology, clinical manifestations, therapy, and outcome were recorded and analyzed. Forty-eight evaluable cases were identified from 1975 to 2012. The number of reported cases increased more than twofold during the study period (P < 0.01). Most cases occurred in the southern United States, India, and Israel. Median age of patients was 25 years, with a male predominance. Most infections were due to E. rostratum (60.4%), followed by E. longirostratum (6.3%) and E. mcginnisii (2%), while 31.3% were unidentified species. The most frequent underlying conditions were immunosuppression (27.2%), trauma (16.6%), and atopy (12.5%). Exserohilum disease manifested as systemic (73%), cutaneous (25%), corneal (16.7%), and subcutaneous (10.4%) infection. Antifungal therapy consisted mainly of amphotericin B (44%) alone or combined with a triazole. Surgery was used in 48% of cases and was combined with antifungal therapy in 31%. The all-cause mortality was 23%, which was higher in patients with preexisting immunosuppression (56.2%; odds ratio 15.4; 95% confidence interval, 2.7-88.6). This 
Introduction
The genus Exserohilum (family Pleosporaceae, order Pleosporales) consists of phaeoid or dematiaceous filamentous fungi characterized by long, multidistoseptate conidia with protruding hilum and the formation of dark colonies [1, 2] . Approximately 35 species belong to the genus Exserohilum. Some are host specific; however, only three, E. rostratum, E. longirostratum, and E. mcginnisii, are pathogenic for humans. Recent taxonomic and molecular studies have shown a high homology between these three species, indicating that they could be the same species [3, 4] .
Exserohilum species are environmental fungi that are common in grass and soil and less common in marine environments. They are considered to be cosmopolitan pathogens, although they occur mainly in warm tropical and subtropical areas [5] . Exserohilum infections have been identified in both immunosuppressed and immunocompetent patients and cause a wide range of topical and systemic diseases [2, 5, 6] .
The ongoing tragic outbreak in the United States has resulted in 61 deaths and more than 750 cases of E. rostratum infections, including meningitis and paraspinal, spinal, and peripheral joint infections [7] . These infections, which arose from injection of contaminated methylprednisolone solution, warrant improved understanding of infections caused by this rare pathogen [8, 9] . Thus, our objective was to systematically review all cases of Exserohilum spp. infections published before the outbreak in order to provide a better understanding of the organism and its role as an etiologic agent of fungal disease in humans.
Patients and Methods
Case reports and case series published in the Medline database (National Library of Medicine, Bethesda, MD, USA) from 1966 to 2012 were included in this study. We looked for the terms "Exserohilum," "Drechslera halodes," "Drechslera longirostrata," "Drechslera rostrata," "Bipolaris halodes," "Bipolaris rostrata," "Helminthosporium halodes," "Helminthosporium rostrata," "Luttrellia rostrata," and "Setosphaeria rostrata." As fungal taxonomy is constantly evolving, we used the most recent nomenclature [10] . Additional information was obtained by following the reference citations from retrieved articles. Only English-language articles were included.
Definitions
Cases were included if all of the following criteria were present: (1) clinical picture consistent with infection and (2) microbiological and/or histological identification of Exserohilum spp. Documentation of the infection could be either premortem or postmortem. Cure was defined as resolution of the infection-related symptoms and findings without reported relapses. Exserohilum infections were classified according to the clinical classification system suggested by McGinnis [11] . According to this classification system, phaeohyphomycosis cases are classified as follows: superficial, cutaneous and corneal, subcutaneous, and systemic infections, which are often initiated in the lungs with subsequent dissemination to other organs and result in a relatively more dismal outcome. Those identified as immunocompromised were considered to be patients who had an underlying hematological malignancy or hematological disorder including, at the minimum, neutropenia or transplantation.
We collected the following data: year of report, country of origin, patient demographics, underlying conditions, precipitating events, clinical manifestations, pathological findings, diagnostic tests, Exserohilum species, antifungal susceptibility profile (when reported), therapy, and outcome.
Data were analyzed with descriptive statistics using the statistical package for the social sciences for Windows (version 20; SPSS, Chicago, IL, USA) software. Continuous variables were summarized using the median and range; categorical variables were summarized using frequencies and percentages. To identify any plausible differences in the demographic and clinical characteristics, a χ 2 or Fisher exact test, where appropriate (for categorical variables), and Student t test or Mann-Whitney test (for continuous variables) were used. A two tailed P-value of <0.05 was considered significant.
Results
From 1975 through 2012 when the US outbreak occurred, 49 cases of Exserohilum spp. infections were published [1, 4, 5, . Among these, 48 fulfilled the predefined criteria for evaluation (one case was published in a nonEnglish language and was excluded from our analysis; Table 1 ) [25] . As shown in Figure 1 , the reports of Exserohilum spp. infections increased more than twofold (χ 2 test for goodness of fit, P < 0.01) during the study period.
Demographic characteristics and underlying conditions
Of the 48 patients with Exserohilum spp. infections, the median age was 25 years (range, <1 month-74 years), with a male predominance (65.9%; Table 2 ). The majority of patients (79%) had an underlying condition, while an appreciable proportion (27.2%) was heavily immunosuppressed (ie, underlying hematological malignancy or transplantation) followed by patients with trauma (17%) and atopy (12.7%). Nine (19.1%) of 47 patients with data on underlying conditions had no apparent risk factor for infection ( Table 2) .
Sites of infection
The most common kind of Exserohilum infection was systemic, occurring in 35 (72.8%) of the 48 patients, followed by cutaneous and corneal infections seen in 20 (41.6%) and subcutaneous seen in 5 (10.4%) cases. Sinuses were affected in almost half of the cases. Of note, before the US outbreak, central nervous system (CNS) infection was reported in only one (2%) patient, and this was part of a disseminated infection that also involved the skin and lungs [30] . The one case of endocarditis subsequently caused vertebral arthritis [28] (Table 3) .
Microbiological data
All patients had only one Exserohilum species recovered, most were from tissue biopsies of the skin, cornea, or sinus mucosa. Exserohilum rostratum was identified ) of the total cases and four (20%) of the immunocompromised patients lacked age and sex data. † One case lacked data on underlying conditions. ‡ One case with hemophagocytic lymphohistiocytosis, four with aplastic anemia, one with idiopathic thrombocytopenia, and one with severe liver disease. § Two cases with stem cell transplantation and one with cardiac transplantation. # Five cases with eye trauma and three with leg trauma. Among these patients, three were farmers and one was a fisherman; these patients were exposed to vegetable material or animal injury. Three cases with asthma, two with nasal polyps, and one with allergic rhinitis and nasal polyps. * * One was a cocaine user and one underwent heart surgery. in 60.4% of the cases, E. longirostratum in 6.3%, and E. mcginnisii in 2%, while in 31.3% of the cases the Exserohilum spp. was unidentified. Bacteria and other fungi were identified in 7 (14.6%) of the 48 patients during the course of the Exserohilum infection. Minimal inhibitory concentrations at 48 h were generated for amphotericin B and some of the azoles in selected cases (Table 4 ) [13, 21, 28, 29, 35, 38, 39, 46] . Culture-independent diagnostic methods by means of polymerase chain reaction (PCR)-based DNA sequencing were applied on corneal scraping, nasal swab, and nasal mucosa in only three cases [4, 20, 23] .
Therapy and outcome
The management of patients with Exserohilum infection is summarized in Table 5 . Fifteen (35%) patients were treated sinus) and, in one case, enucleation of the infected eye [42] . All but three (7.0%) patients received some type of therapy. Among the nontreated patients, two were suffering from cutaneous infection and one from keratitis. The patient with keratitis was cured without treatment, while the patient with cutaneous infection (a neonate with hemophagocytic lymphohistiocytosis) died. The third patient, who did not receive therapy, did not have apparent risk factors for infection and was lost to follow-up. The antifungal agent most frequently used was amphotericin B (either in its conventional form or as a lipid formulation) followed by azoles (most frequently ketoconazole); other classes of antifungal agents (micafungin and flucytosine) were used in two patients each. Thirteen of 32 patients who received antifungal agents (41%) received more than one antifungal agent throughout their treatment course in sequence or in combination. The most common combination treatment was amphotericin B with itraconazole (received by four patients), followed by amphotericin B with ketoconazole (three patients), amphotericin B with flucytosine (two patients), amphotericin B with micafungin (one patient), and amphotericin B with voriconazole (one patient). Amphotericin B was the antifungal agent used exclusively in pediatric patients either alone (five patients) or in combination with an azole (voriconazole or itraconazole, five patients) or flucytosine (two patients). Two patients with aplastic anemia received granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor [13, 31] .
The all-cause mortality was 26% (11 of 42 patients for whom outcome was reported). In patients with preexisting immunosuppression (hematological malignancies, other hematological disorders, and transplantation), the mortality rate was 56% (9 of 16 immunosuppressed patients) compared with immunocompetent patients, for whom the mortality rate was 7.7% (2 of 26 immunocompetent patients; odds ratio 15.4; 95% confidence interval, 2.7-88.6; P = 0.001). Mortality did not differ between pediatric and adult population (29.4% vs. 26%, P = 0.8).
Geographic distribution
The majority of patients (23 cases) were from the United States; 20 were from the eastern region. Seven cases were reported from India, six from Israel, four from East Asia, two from Central America, and two from Canada. One case was reported from each of the following countries: France, Australia, South Africa, and Japan.
Discussion
Our analysis of the 48 cases identified important features of Exserohilum spp. infection. The ongoing outbreak of meningitis, with its profound medical implications, has brought into focus many lingering questions regarding fungal pathogenesis, epidemiology, diagnosis, treatment, and prognosis.
The number of case reports of Exserohilum spp. infections has been increasing in the last decade. From 1975, when the first case was reported in the English literature, to 1990, there were 13 cases. Among these, only four (30.7%) were apparently immunodeficient. In the last decade, 20 cases have been reported, with 15 (75%) being immunosuppressed (mainly due to hematological malignancies and chemotherapy-induced immunosuppression). As has been suggested in phaeohyphomycosis, the main reason for this increase in the number of Exserohilum cases may be iatrogenic immunodeficiency [6] and possibly improved diagnostic procedures; however, this could, at least in part, represent publication bias. In addition, in our reviewed cases, Exserohilum infection occurred as a result of disruption of mucocutaneous barriers after trauma [15, 20, 34, [41] [42] [43] or surgery [28] or in patients with underlying atopic pathology [46, 49, 51] . However, rarely, Exserohilum spp. caused infection in immunocompetent individuals without any apparent underlying condition [30, 39, 40, 44, 45, 51] . Little is known regarding the pathogenic mechanism by which dematiaceous fungi cause disease, especially in immunocompetent hosts. One popular virulence factor, which is common to all dematiaceous fungi, is the presence of melanin in the cell wall. Although few species have been studied, multiple mechanisms by which melanin may act as a virulence factor have been proposed, including its function as antioxidant and radioprotectant, causing sequestration of host defense proteins and shielding cell wall constituents against hydrolytic enzymes or conferring resistance to heat or to antifungal agents [2] .
Exserohilum spp. infection is, in most cases, a systemic infection that affects primarily the sinuses and lungs. It is interesting to note that only one Exserohilum CNS case in a young immunocompetent patient has been published since 1975 [30] . It was not until 2012 when Exserohilum's propensity to cause meningitis was noted [8] . Contamination of a preservative-free methylprednisolone injection preparation resulted in more than 300 cases of Exserohilum meningitis and approximately 60 deaths in a multistate US outbreak [7] . It is not known whether there is "tropism" of E. rostratum to infect the CNS or whether corticosteroids accelerated growth and metabolism of E. rostratum along with other potential fungal virulence factors and innate host defects, rendering these patients more susceptible to infection [53] . Nevertheless, in apparently immunocompetent individuals, the main predisposing factors for Exserohilum infection were trauma and atopy [41] [42] [43] 46, 47, 51] .
While the majority of keratomycoses are caused by hyaline fungi such as Aspergillus spp. and Fusarium spp., the diagnosis of Exserohilum keratitis in 17% of our reviewed patients is noteworthy. Exserohilum keratitis occurred as the primary infection in apparently immunocompetent patients. In the majority of patients this was followed by corneal trauma from contaminated plants. The survival rates in this group of patients were high; however, half of them were cured and the remaining had nonreversible visual deficits. Although the optimal medical interventions for the management of fungal keratitis remain largely unknown, in our reviewed cases, natamycin was the most frequently used topical antifungal agent.
What is particularly distinctive in Exserohilum cases is the absence of positive blood cultures, even in patients with disseminated infection. However, PCR-positive signals have been detected recently in some infected patients [Y. Zhao and D.S. Perlin, unpublished results]. In contrast, other agents of phaeohyphomycosis-like Scedosporium prolificans are associated with particularly high rates of fungemia [6] . Further investigation is needed to determine whether this is due to low-level fungemia of Exserohilum spp. or to low sensitivity of culture methods or is related to the presence or absence of other virulence factors.
In all cases, the infection was laboratory confirmed by culture and histopathology based on morphological findings; the PCR assay was helpful in identifying the pathogen in only a few cases [4, 20, 23] . Given the variability of the morphological characteristics of Exserohilum spp., which make definitive recognition difficult, and the importance of the fungus' rapid and precise identification, the potential of using a PCR assay is invaluable. In view of the ongoing meningitis cases, there was an unprecedented need for development of a quantitative PCR system that is specific for E. rostratum. Recently, molecular assays have been developed to detect the fungal DNA in human body fluids and tissues and to quantitatively evaluate and monitor E. rostratum infection [54, 55] . The cell wall carbohydrate polymer, 1-3-β-D-glucan, has been proposed as an additional biomarker as it is useful when diagnosing and monitoring Exserohilum infection [53] .
In vitro antifungal susceptibility testing performed in some of the reviewed reports showed sensitivity to amphotericin B, itraconazole, and voriconazole and resistance to flucytosine and usually ketoconazole [13, 21, 28, 29, 35, 38, 46] . Susceptibility data for Exserohilum spp. vary greatly, likely reflecting the different procedures used for susceptibility testing. In a recent study where a large panel of Exserohilum clinical isolates was evaluated among the antifungal agents tested, amphotericin B, itraconazole, posaconazole, voriconazole, and terbinafine showed relatively low minimal inhibitory concentrations (MICs), while the echinocandins showed relatively high MICs [3] . To date, the US Centers for Disease Control and Prevention Fungus Reference Laboratory has tested 50 clinical E. rostratum isolates from the 2012 outbreak. The MICs for voriconazole, fluconazole, itraconazole, posaconazole, isavuconazole, and amphotericin B ranged from 1 to 4, 16 to 256, 0.25 to 4, 0.25 to 1, 2 to 4, and 0.032 to 2 μg/ml, respectively, while susceptibility testing for echinocandins was not performed [56] . Consistently, the in vitro susceptibility data show that the azoles, with the exception of fluconazole and amphotericin B, have excellent activity against the fungus.
In the absence of controlled clinical trials on optimal anti-Exserohilum therapy, treatment options are based almost entirely on in vitro data and published case reports. On the basis of the cases reviewed here, amphotericin B alone, or in combination with an azole, was the drugs most commonly used. Amphotericin B was initially administered to all patients with systemic disease. The role of echinocandins in the management of Exserohilum infections is less well defined, as these agents generally have minor antifungal activity against the dematiaceous molds [57] . Consistent with this lack of activity against most dematiaceous fungi, a small retrospective study of patients on caspofungin prophylaxis after hematopoietic stem cell transplantation identified one case of breakthrough Exserohilum infection among nine breakthrough invasive fungal infections [22] .
Combination treatment in the reviewed cases was mainly part of a salvage therapy used with the rationale of providing a broader spectrum antifungal coverage. Synergy between amphotericin B and ketoconazole was observed in one case with vertebral osteomyelitis following endocarditis [28] . Although ketoconazole is seldom used currently in the treatment of human mycoses, this study does show the potential of synergistic interaction between a hydrophobic azole and a polyene against E. rostratum. Nonetheless, the effectiveness of combination antifungal therapy with the triazoles, such as itraconazole, voriconazole, and posaconazole, against Exserohilum infections has not yet been defined in vitro or in vivo [53] .
Isavuconazole is a new antifungal triazole that was recently studied in vitro against E. rostratum. Isavuconazole was active against E. rostratum at concentrations of 0.5-4.0 μg/ml. Amphotericin B was the most active antifungal agent and induced the most structural damage. An expert panel was established after the E. rostratum outbreak in the United States. Taking into account the in vitro susceptibilities of the pathogen and the pharmacologic features of each antifungal agent, this panel recommended use of voriconazole as primary therapy for meningitis and the addition of a lipid formulation of amphotericin B for those with severe extraneural disease and patients with advanced CNS or refractory infections [57] .
On some occasions, however, especially in patients with persistent symptoms or clinical deterioration despite antifungal treatment, surgical intervention, by means of debridement of the infected tissue, may be warranted for successful eradication. Further development of alternative antifungal strategies and new approaches for therapeutic monitoring are needed for optimal management of CNS infection [53] .
The differences between the reviewed cases and the population implicated in the outbreak associated with the contaminated methylprednisolone in Tennessee [8] are easily discernible. The reviewed patients were young (median age 25 years, range 26 days-74 years, while 35% of the patients were children) and had apparent underlying predisposing conditions; most were heavily immunosuppressed and the manifestations from the respiratory tract predominated. On the contrary, the outbreak patients were relatively old (median age 69 years, range 23-91 years, with no pediatric patients), they did not have any apparent risk factors for infection, except for the accidental injection of the contaminated methylprednisolone solution, and they presented with CNS manifestations. Nevertheless, based on our past and present experience, the following assumptions could be made regarding this potentially catastrophic pathogen: Exserohilum infection is an "iatrogenic" infection that occurs as a result either of "iatrogenic" immunodeficiency or "iatrogenic" implantation, there is a "tropism" to specific organs and systems related to the fungus' portal of entry, and approximately one of four infected patients would have a dismal end.
Given the retrospective and literature review nature of this study, it is difficult to make definitive conclusions about Exserohilum spp. epidemiology and outcome. In addition, it is difficult to suggest approaches for diagnosis or therapy, as there appear to be lingering issues that need to be elucidated through further studies. Nevertheless, this review could be of interest because data on Exserohilum infections were limited to individual case reports. The strength of this study is that it is, to our knowledge, the most comprehensive review of published cases of infections caused by Exserohilum spp. before the onset of the ongoing US outbreak.
Collectively, from our review, it has become clear that Exserohilum can cause a wide spectrum of diseases, ranging from less invasive to more invasive, with significant mortality and affecting both immunocompetent and immunocompromised hosts. These observations, together with the near ubiquitous nature of Exseruhilum spp., constitute an alarming issue, indicating that under permissive circumstances (a striking example is the US outbreak) the fungus can emerge to be a significant pathogen. Given the lack of data regarding epidemiology, disease pathogenesis, and effective treatment options, the development of suitable in vitro and in vivo Exserohilum infection models constitutes a research priority.
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